Edward J Goetzl1,2, Janice B Schwartz1,2,3, Erin L Abner4, Gregory A Jicha4, Dimitrios Kapogiannis5. 1. Department of Medicine, University of California, San Francisco, San Francisco, CA. 2. Jewish Home of San Francisco, San Francisco, CA. 3. Department of Bioengineering, University of California, San Francisco, San Francisco, CA. 4. Sanders-Brown Center for Aging Research, University of Kentucky, Lexington, KY. 5. Laboratory of Neurosciences, National Institute on Aging, Baltimore, MD.
Abstract
OBJECTIVE: Astrocytes fulfill neuronal trophic roles normally, but are transformed in Alzheimer disease (AD) into A1-type reactive astrocytes that may destroy neurons through unknown mechanisms. METHODS: To investigate astrocyte inflammatory mechanisms, astrocyte-derived exosomes (ADEs) were isolated immunochemically from plasma samples of AD patients and matched controls for enzyme-linked immunosorbent assay quantification of complement proteins. RESULTS: ADE levels of C1q, C4b, C3d, factor B, factor D, Bb, C3b, and C5b-C9 terminal complement complex, but not mannose-binding lectin, normalized by the CD81 exosome marker were significantly higher for AD patients (n = 28) than age- and gender-matched controls (all p < 0.0001). ADE normalized levels of interleukin (IL)-6, tumor necrosis factor-α, and IL-1β were significantly higher for AD patients than controls, but there was greater overlap between the two groups than for complement proteins. Mean ADE levels of complement proteins for AD patients in a longitudinal study were significantly higher (n = 16, p < 0.0001) at the AD2 stage of moderate dementia than at the AD1 preclinical stage 5 to 12 years earlier, which were the same as for controls. ADE levels of complement regulatory proteins CD59, CD46, decay-accelerating factor (DAF), and complement receptor type 1, but not factor I, were significantly lower for AD patients than controls (p < 0.0001 for CD59 and DAF), were diminished by the AD1 stage, and were further decreased at the AD2 stage. INTERPRETATION: ADE complement effector proteins in AD are produced by dysregulated systems, attain higher levels than in controls, and may potentially damage neurons in the late inflammatory phase of AD. Ann Neurol 2018;83:544-552.
OBJECTIVE: Astrocytes fulfill neuronal trophic roles normally, but are transformed in Alzheimer disease (AD) into A1-type reactive astrocytes that may destroy neurons through unknown mechanisms. METHODS: To investigate astrocyte inflammatory mechanisms, astrocyte-derived exosomes (ADEs) were isolated immunochemically from plasma samples of ADpatients and matched controls for enzyme-linked immunosorbent assay quantification of complement proteins. RESULTS:ADE levels of C1q, C4b, C3d, factor B, factor D, Bb, C3b, and C5b-C9 terminal complement complex, but not mannose-binding lectin, normalized by the CD81 exosome marker were significantly higher for ADpatients (n = 28) than age- and gender-matched controls (all p < 0.0001). ADE normalized levels of interleukin (IL)-6, tumor necrosis factor-α, and IL-1β were significantly higher for ADpatients than controls, but there was greater overlap between the two groups than for complement proteins. Mean ADE levels of complement proteins for ADpatients in a longitudinal study were significantly higher (n = 16, p < 0.0001) at the AD2 stage of moderate dementia than at the AD1 preclinical stage 5 to 12 years earlier, which were the same as for controls. ADE levels of complement regulatory proteins CD59, CD46, decay-accelerating factor (DAF), and complement receptor type 1, but not factor I, were significantly lower for ADpatients than controls (p < 0.0001 for CD59 and DAF), were diminished by the AD1 stage, and were further decreased at the AD2 stage. INTERPRETATION:ADE complement effector proteins in AD are produced by dysregulated systems, attain higher levels than in controls, and may potentially damage neurons in the late inflammatory phase of AD. Ann Neurol 2018;83:544-552.
Authors: Jason J Corneveaux; Amanda J Myers; April N Allen; Jeremy J Pruzin; Manuel Ramirez; Anzhelika Engel; Michael A Nalls; Kewei Chen; Wendy Lee; Kendria Chewning; Stephen E Villa; Hunsar B Meechoovet; Jill D Gerber; Danielle Frost; Hollie L Benson; Sean O'Reilly; Lori B Chibnik; Joshua M Shulman; Andrew B Singleton; David W Craig; Kendall R Van Keuren-Jensen; Travis Dunckley; David A Bennett; Philip L De Jager; Christopher Heward; John Hardy; Eric M Reiman; Matthew J Huentelman Journal: Hum Mol Genet Date: 2010-06-09 Impact factor: 6.150
Authors: Jennifer L Zamanian; Lijun Xu; Lynette C Foo; Navid Nouri; Lu Zhou; Rona G Giffard; Ben A Barres Journal: J Neurosci Date: 2012-05-02 Impact factor: 6.167
Authors: Stefan J Cano; Holly B Posner; Margaret L Moline; Stephen W Hurt; Jina Swartz; Tim Hsu; Jeremy C Hobart Journal: J Neurol Neurosurg Psychiatry Date: 2010-09-29 Impact factor: 10.154
Authors: H Zanjani; C E Finch; C Kemper; J Atkinson; D McKeel; J C Morris; J L Price Journal: Alzheimer Dis Assoc Disord Date: 2005 Apr-Jun Impact factor: 2.703
Authors: Andrew W Kraft; Xiaoyan Hu; Hyejin Yoon; Ping Yan; Qingli Xiao; Yan Wang; So Chon Gil; Jennifer Brown; Ulrika Wilhelmsson; Jessica L Restivo; John R Cirrito; David M Holtzman; Jungsu Kim; Milos Pekny; Jin-Moo Lee Journal: FASEB J Date: 2012-10-04 Impact factor: 5.191
Authors: Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski Journal: Ann Neurol Date: 2009-04 Impact factor: 10.422
Authors: Pavan Bhargava; Carlos Nogueras-Ortiz; Sol Kim; Francheska Delgado-Peraza; Peter A Calabresi; Dimitrios Kapogiannis Journal: Mult Scler Date: 2020-06-17 Impact factor: 6.312